JP2022518060A5 - - Google Patents

Info

Publication number
JP2022518060A5
JP2022518060A5 JP2021543372A JP2021543372A JP2022518060A5 JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5 JP 2021543372 A JP2021543372 A JP 2021543372A JP 2021543372 A JP2021543372 A JP 2021543372A JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
individual
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543372A
Other languages
English (en)
Japanese (ja)
Other versions
JP7712206B2 (ja
JP2022518060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015455 external-priority patent/WO2020160020A1/en
Publication of JP2022518060A publication Critical patent/JP2022518060A/ja
Publication of JP2022518060A5 publication Critical patent/JP2022518060A5/ja
Priority to JP2025115594A priority Critical patent/JP2025148430A/ja
Application granted granted Critical
Publication of JP7712206B2 publication Critical patent/JP7712206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543372A 2019-01-28 2020-01-28 多発性骨髄腫の処置方法 Active JP7712206B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115594A JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962797876P 2019-01-28 2019-01-28
US62/797,876 2019-01-28
US201962847826P 2019-05-14 2019-05-14
US62/847,826 2019-05-14
US201962861954P 2019-06-14 2019-06-14
US62/861,954 2019-06-14
US201962899094P 2019-09-11 2019-09-11
US62/899,094 2019-09-11
US201962931014P 2019-11-05 2019-11-05
US62/931,014 2019-11-05
EP19306554 2019-12-03
EP19306554.7 2019-12-03
US201962943716P 2019-12-04 2019-12-04
US62/943,716 2019-12-04
PCT/US2020/015455 WO2020160020A1 (en) 2019-01-28 2020-01-28 Methods of treating multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115594A Division JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Publications (3)

Publication Number Publication Date
JP2022518060A JP2022518060A (ja) 2022-03-11
JP2022518060A5 true JP2022518060A5 (https=) 2023-02-22
JP7712206B2 JP7712206B2 (ja) 2025-07-23

Family

ID=69646031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543372A Active JP7712206B2 (ja) 2019-01-28 2020-01-28 多発性骨髄腫の処置方法
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Country Status (15)

Country Link
US (2) US11939390B2 (https=)
EP (2) EP3917961A1 (https=)
JP (2) JP7712206B2 (https=)
KR (1) KR20210120048A (https=)
CN (2) CN120754030A (https=)
AU (1) AU2020215692A1 (https=)
BR (1) BR112021014699A2 (https=)
CA (1) CA3127928A1 (https=)
CO (1) CO2021011034A2 (https=)
IL (2) IL321343A (https=)
MA (1) MA54860A (https=)
MX (1) MX2021009079A (https=)
SG (1) SG11202108029XA (https=)
TW (2) TW202535952A (https=)
WO (1) WO2020160020A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
JP6730260B2 (ja) 2014-09-12 2020-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬
JP7712206B2 (ja) 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
EP3969004A1 (en) * 2019-05-14 2022-03-23 Sanofi Methods of administering anti-cd38 antibody to treat multiple myeloma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL293563A (en) * 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
EP4192511A1 (en) * 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
US20240058464A1 (en) * 2021-01-07 2024-02-22 Fortis Therapeutics, Inc. Combination therapy with for46 for cancer
CN114219787B (zh) * 2021-12-17 2024-08-06 三峡大学 一种初诊多发性骨髓瘤预后分期系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
LT2882441T (lt) * 2012-08-09 2020-07-27 Celgene Corporation Su imunitetu susijusių ir uždegiminių ligų gydymas
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
IL256242B2 (en) * 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
US20180153989A1 (en) * 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
JP7712206B2 (ja) 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法

Similar Documents

Publication Publication Date Title
JP2022518060A5 (https=)
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP2023517236A5 (https=)
TWI890481B (zh) 雙特異性抗體
JP2021502961A5 (https=)
JP2005533861A5 (https=)
US12527784B2 (en) Combined pharmaceutical composition for treating small cell lung cancer
JP2020509031A5 (https=)
CA2707400A1 (en) Method for treating bone fracture with anti-sclerostin antibodies
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
JP2021515017A5 (https=)
JP2021534165A5 (https=)
JP2019516767A (ja) 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ
JP2023515675A5 (https=)
CN117980002A (zh) 癌症治疗组合
JP2023510199A5 (https=)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2024537864A5 (https=)
JP2021523138A5 (https=)
JP2022514561A5 (https=)
JP2023505219A5 (https=)
WO2025122791A1 (en) Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma
JP2023523568A5 (https=)
JP2022531205A5 (https=)
JP2023550311A5 (https=)